Navigation Links
In vivo Study Results Demonstrating Potential of Alfacell's,Onconase for Treatment of Non-Small Cell Lung Cancer Published in,Anticancer Research

y making these forward-looking statements, the company undertakes no obligation to update these statements for revisions or changes after the date of this release.

    Media Contact:                    Investor Contact:

    David Schull or Wendy Lau         Andreas Marathovouniotis

    Noonan Russo                      Noonan Russo

    212-845-4271                      212-845-4253
david.schull@eurorscg.com andreas.marathis@eurorscg.com wendy.lau1@eurorscg.com

CONTACT: Media: David Schull, , or Wendy Lau,, +1-212-845-4271, or Investors: AndreasMarathovouniotis, , +1-212-845-4253, all ofNoonan Russo for Alfacell Corporation david.schull@eurorscg.com wendy.lau1@eurorscg.com andreas.marathis@eurorscg.com

Web site: http://www.alfacell.com/

Ticker Symbol: (NASDAQ-NMS:ACEL)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:7/24/2008)...uscle and Blood Vessel Formation in ... 24 /- Results of a,preclin...dified to express,stromal derived factor-1(alpha) ...dium of rats, which suggest improved heart functio...ngs -- the International Society for,Magnetic Reso...
(Date:7/24/2008)...eeds Oncology Patient Accrual, DENVER, July 24 /P...ent,Organization (RMO), has contracted with five l...h and site management services for their,clinical ...ategy. The new,trials include the following diseas...Metastatic Breast Cancer, Metastatic Sarcoma, Chro...
(Date:7/23/2008)...ic Therapy to Treat the Disease -, WAYNE, N.J. an...l/ --,Bayer HealthCare Pharmaceuticals and Onyx Ph... that The New England Journal of Medicine publishe...xavar(R) (sorafenib),tablets decreased the absolut...esectable hepatocellular carcinoma (HCC), or liver...
(Date:7/23/2008)...uoroPharma Inc., a company developing,breakthrough...n Tomography,(PET) market, announced positive Phas...ed tracer for myocardial perfusion imaging. BFPET ... complete Phase I clinical,development., BFPET is... flow in the,heart (myocardial perfusion). Myocard...
Breaking Medicine Technology:Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study 2Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study 3Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study 4Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study 5Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study 6Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials 2The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 2The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 3The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 4The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 5The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 6FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET) 2FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET) 3ThermoGenesis Announces Receipt of CE Mark for MarrowXpress 28TM 29 6108 1ThermoGenesis Announces Receipt of CE Mark for MarrowXpress 28TM 29 6108 2ThermoGenesis Announces Receipt of CE Mark for MarrowXpress 28TM 29 6108 3Beike Biotech Opens Comprehensive Stem Cell Storage and Processing Facility in China 6105 1Beike Biotech Opens Comprehensive Stem Cell Storage and Processing Facility in China 6105 2Beike Biotech Opens Comprehensive Stem Cell Storage and Processing Facility in China 6105 3Beike Biotech Opens Comprehensive Stem Cell Storage and Processing Facility in China 6105 4Scientists may have solved an ecological riddle 3701 1Scientists may have solved an ecological riddle 3701 2Perspective 3A Policies must keep pace with genetic progress 3698 1Perspective 3A Policies must keep pace with genetic progress 3698 2
(Date:7/25/2008)...erican Society for Gastrointestinal Endoscopy (ASG...in the bariatric surgery patient. The rising preva...ess in surgical interventions led to a marked incr...med in the U.S., from 13,365 in 1998 to 102,794 in...operative patient and the postoperative patient, a...
(Date:7/25/2008)...er of jobs created in the medical field slowed in ...t kind of slowdown: they laid off fewer people in ... Seattle, WA (PRWEB) July 25, 2008 -- Though...lowed in June overall, pharmaceutical companies re...usic to the ears of sales representatives: fewer l...
(Date:7/25/2008)...xclusivity Begins -, CORONA, Calif., July 25 /PRN... (NYSE: WPI ), a leading specialty pharmaceutical...commenced commercial,shipment of its Omeprazole De...ength from its Davie, Florida manufacturing facili... days of marketing exclusivity for being the,first...
(Date:7/25/2008).../ -- Sagent Pharmaceuticals, Inc.,a privately-hel...d that it,has launched amiodarone HCl injection, U...reatment and prophylaxis of frequently recurring,v...le ventricular,tachycardia -- a potentially life-t...ne HCl injection will be available immediately in ...
Breaking Medicine News(10 mins):Health News:ASGE issues guidelines on the role of endoscopy in the bariatric surgery patient 2Health News:ASGE issues guidelines on the role of endoscopy in the bariatric surgery patient 3Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 2Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 3Health News:Watson Launches Omeprazole Delayed-Release Capsules, 40MG 2Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 2Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 3
...new test may be an important tool in the fight aga...ical Electroencephalography highlights the use of ...lier, which may lead to improved treatment. The te... detects impaired memory, which is known to preced...
...ile health experts tirelessly warn that the long-t...kin cancer, the short-term effects can be blazingl... beach. Characterized by bright, red skin that is ...unburn is a sure, almost immediate sign that you d...
...alian researchers claim eating pizza regularly red...rcent. The risk of developing colon cancer also fe...hey claimed. The researchers polled 3,300 people w...phagus, throat or colon and 5,000 people who had n...
...mmon painkillers may lower the risk of developing ... the greater the benefit, scientists said on Frida...ct of painkillers, known as non-steroidal anti-inf...ke them are less likely to develop the illness, wh...
Other Medicine News:
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
Medicine Products: